Impact of resistance training on cardiometabolic health-related indices in patients with type 2 diabetes and overweight/obesity: a systematic review and meta-analysis of randomised controlled trials.
Study Goal
To evaluate the effects of resistance training on cardiometabolic health-related outcomes in patients with type 2 diabetes mellitus (T2DM) and overweight/obesity.
Results Summary
Resistance training improved waist circumference, waist-to-hip ratio, high-density lipoprotein cholesterol, triglycerides, fasting blood glucose, fasting insulin, and glycated hemoglobin compared with standard treatment. The risk of bias was low to unclear, and the quality of evidence was very low to moderate.
Population
Adults diagnosed with T2DM and concurrent overweight/obesity (BMI ≥25 kg/m²).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
resistance training | decrease | waist circumference | patients with type 2 diabetes mellitus (T2DM) and overweight/obesity | standardised mean differences (SMD) -0.85 cm, 95% CI -1.66 to -0.04 | improved | #1 |
resistance training | decrease | waist-to-hip ratio | patients with type 2 diabetes mellitus (T2DM) and overweight/obesity | SMD -0.72, 95% CI -1.30 to -0.15 | improved | #2 |
resistance training | increase | high-density lipoprotein cholesterol | patients with type 2 diabetes mellitus (T2DM) and overweight/obesity | SMD +0.40 mg/dL, 95% CI 0.07 to -0.72 | improved | #3 |
resistance training | decrease | triglycerides | patients with type 2 diabetes mellitus (T2DM) and overweight/obesity | SMD -0.54 mg/dL, 95% CI -1.06 to -0.02 | improved | #4 |
resistance training | decrease | fasting blood glucose | patients with type 2 diabetes mellitus (T2DM) and overweight/obesity | SMD -0.65 mmol/L, 95% CI -1.19 to -0.12 | improved | #5 |
resistance training | decrease | fasting insulin | patients with type 2 diabetes mellitus (T2DM) and overweight/obesity | SMD -0.74 uIU/mL, 95% CI -1.12 to -0.36 | improved | #6 |
resistance training | decrease | glycated haemoglobin | patients with type 2 diabetes mellitus (T2DM) and overweight/obesity | SMD -0.32%, 95% CI -0.63 to -0.01 | improved | #7 |
resistance training | neutral | cardiometabolic health-related outcomes | patients with type 2 diabetes mellitus (T2DM) and concurrent overweight/obesity | - | is associated with many cardiometabolic benefits | #8 |
OBJECTIVE: To evaluate the effects of resistance training on cardiometabolic health-related outcomes in patients with type 2 diabetes mellitus (T2DM) and overweight/obesity. DESIGN: Systematic review and meta-analysis of randomised controlled trials (RCTs). DATA SOURCES: PubMed, Web of Science, Scopus, Science Direct, Cochrane Library and Google Scholar databases were searched from inception up to May 2024. The search strategy included the following keywords: diabetes, resistance exercise and strength training. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: RCTs published in English comparing resistance training alone with non-exercising standard treatment. Participants were adults diagnosed with T2DM and concurrent overweight/obesity (body mass index (BMI) ≥25 kg/m2). RESULTS: A total of 18 RCTs qualified involving 1180 patients (48.6/51.4 female/male ratio; 63.3±7.0 years; 29.3±4.3 kg/m2). Waist circumference (standardised mean differences (SMD) -0.85 cm, 95% CI -1.66 to -0.04), waist-to-hip ratio (SMD -0.72, 95% CI -1.30 to -0.15), high-density lipoprotein cholesterol (SMD +0.40 mg/dL, 95% CI 0.07 to -0.72), triglycerides (SMD -0.54 mg/dL, 95% CI -1.06 to -0.02), fasting blood glucose (SMD -0.65 mmol/L, 95% CI -1.19 to -0.12), fasting insulin (SMD -0.74 uIU/mL, 95% CI -1.12 to -0.36) and glycated haemoglobin (SMD -0.32%, 95% CI -0.63 to -0.01) improved compared with standard treatment. The risk of bias was low to unclear, and the quality of evidence was very low to moderate. CONCLUSIONS: Resistance training as a standalone exercise intervention in the management and treatment of T2DM with concurrent overweight/obesity is associated with many cardiometabolic benefits when compared with standard treatment without exercise. PROSPERO REGISTRATION NUMBER: CRD42022355612.